These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Bird ED; Spokes EG; Iversen LL Acta Psychiatr Scand Suppl; 1980; 280():63-73. PubMed ID: 6447433 [No Abstract] [Full Text] [Related]
3. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Silvestroni A; Faull RL; Strand AD; Möller T Neuroreport; 2009 Aug; 20(12):1098-103. PubMed ID: 19590393 [TBL] [Abstract][Full Text] [Related]
4. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea. Finch CE Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874 [No Abstract] [Full Text] [Related]
5. Fluorescence studies of fibroblasts, lymphocytes, and erythrocytes in Huntington's disease. Pettegrew JW; Nicholas JS; Stewart RM Trans Am Neurol Assoc; 1979; 104():61-6. PubMed ID: 162257 [No Abstract] [Full Text] [Related]
6. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Ide K; Nukina N; Masuda N; Goto J; Kanazawa I Biochem Biophys Res Commun; 1995 Apr; 209(3):1119-25. PubMed ID: 7733967 [TBL] [Abstract][Full Text] [Related]
8. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
9. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Freeman W; Morton AJ Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238 [TBL] [Abstract][Full Text] [Related]
10. Huntington's disease: a monogenic disorder with cellular and biochemical complexities. Bhattacharyya NP FEBS J; 2008 Sep; 275(17):4251. PubMed ID: 18637948 [No Abstract] [Full Text] [Related]
11. Animal models of Huntington's disease. Gárdián G Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874 [TBL] [Abstract][Full Text] [Related]
15. Impairment of energy metabolism and excitotoxic cell death in Huntington disease. Young AB Rev Neurol (Paris); 1997 Sep; 153(8-9):496-8. PubMed ID: 9683998 [TBL] [Abstract][Full Text] [Related]
16. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Gil JM; Rego AC Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572 [TBL] [Abstract][Full Text] [Related]
17. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Curtis MA; Faull RL; Glass M J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591 [TBL] [Abstract][Full Text] [Related]
18. Towards a therapy for Huntington's disease (Commentary on Giampà et al.). Hannan AJ Eur J Neurosci; 2009 Mar; 29(5):901. PubMed ID: 19291220 [No Abstract] [Full Text] [Related]
20. Huntington's disease and neurogenesis: FGF-2 to the rescue? La Spada AR Proc Natl Acad Sci U S A; 2005 Dec; 102(50):17889-90. PubMed ID: 16330780 [No Abstract] [Full Text] [Related] [Next] [New Search]